Buccal tablet formula capable of increasing content of nicotinamide mononucleotide

Abstract

The invention belongs to the technical field of health care product formulas, and particularly relates to a buccal tablet formula capable of increasing the content of nicotinamide mononucleotide, which comprises the following components in parts by weight: 20-30 parts of nicotinamide mononucleotide; 6 to 12 parts of a nano-scale fullerene inclusion; 5 to 20 parts of fructo-oligosaccharide; 6 to 17 parts of microcrystalline cellulose; 5 to 10 parts of lactose; 3 to 10 parts of mannitol; 2 to 4 parts of hydroxypropyl methyl cellulose; 0.3 to 1 part of magnesium stearate; 1-5 parts of a spina date seed extract; 1-5 parts of a ginkgo leaf extract; 3-7 parts of vitamins; and 0.5-2 parts of fruit juice concentrate. The content of nicotinamide mononucleotide can be effectively increased, the stability is enhanced, and the absorption and utilization rate is increased.

Description

Technical Field

[0001] The present invention belongs to the technical field of health care product formulas, and particularly relates to a lozenge formula capable of increasing the content of nicotinamide mononucleotide. Background Art

[0002] Nicotinamide mononucleotide (NMN), a precursor of NAD+, a cofactor for longevity proteins in the human body, plays a vital role in maintaining cell health, promoting metabolism, and delaying aging. As people's health awareness increases, the demand for NMN-related products is growing.

[0003] Existing technology prepares lozenges by simply mixing NMN with conventional excipients (starch ingredients are added to some lozenges). NMN is easily affected by environmental factors and degraded during storage, resulting in a decrease in the actual effective content; and the conventional lozenge dosage form makes the release and absorption pattern of NMN in the mouth and gastrointestinal tract poor, making it difficult to fully exert its efficacy. Summary of the Invention

[0004] The purpose of the present invention is to provide a lozenge formula that can increase the content of nicotinamide mononucleotide, which can effectively increase the content of nicotinamide mononucleotide, enhance stability and improve absorption and utilization rate.

[0005] The technical solutions adopted by the present invention are as follows:

[0006] A lozenge formula for increasing the content of nicotinamide mononucleotide, comprising the following ingredients in parts by weight:

[0007] Nicotinamide mononucleotide: 20-30 copies;

[0008] Nano-scale fullerene inclusions: 6-12 parts;

[0009] Fructooligosaccharides: 5-20 parts;

[0010] Microcrystalline cellulose: 6-17 parts;

[0011] Lactose: 5-10 parts;

[0012] Mannitol: 3-10 parts;

[0013] Hydroxypropyl methylcellulose: 2-4 parts;

[0014] Magnesium stearate: 0.3-1 part;

[0015] Ziziphus jujuba seed extract: 1-5 parts;

[0016] Ginkgo biloba extract: 1-5 parts;

[0017] Vitamins: 3-7 parts, including at least one of the following combinations: 1-3 parts vitamin B3 (niacinamide) + 1-2 parts vitamin C + 0.5-1 part vitamin E; 2-4 parts vitamin B complex (B1 / B2 / B6) + 0.5-1 part folic acid;

[0018] Juice concentrate: 0.5-2 parts, selected from concentrated juice (solids ≥ 70%) of low water activity fruits (such as blueberries, black currants, cranberries), avoid using citrus (highly acidic) or melon (high in water).

[0019] The specific components are measured by weight:

[0020] Nicotinamide mononucleotide: 20 parts; nano-fullerene inclusions: 6 parts; oligofructose: 10 parts; microcrystalline cellulose: 8 parts; lactose: 6 parts; mannitol: 5 parts; hydroxypropyl methylcellulose: 1.5 parts; magnesium stearate: 0.5 parts; spinach seed extract: 1.5 parts; ginkgo leaf extract: 1.5 parts; vitamins: 3.5 parts; fruit juice concentrate: 1 part.

[0021] Nicotinamide mononucleotide: 30 parts; nano-fullerene inclusions: 10 parts; oligofructose: 17 parts; microcrystalline cellulose: 15 parts; lactose: 8 parts; mannitol: 8 parts; hydroxypropyl methylcellulose: 3 parts; magnesium stearate: 0.8 parts; spiny jujube seed extract: 2.5 parts; ginkgo leaf extract: 2.5 parts; vitamins: 5 parts; fruit juice concentrate: 1.5 parts.

[0022] A method for preparing a lozenge capable of increasing the content of nicotinamide mononucleotide comprises the following steps:

[0023] S1: According to the formula ratio, accurately weigh nicotinamide mononucleotide, nano-fullerene inclusions, oligofructose, microcrystalline cellulose, lactose, mannitol, jujube seed extract, ginkgo leaf extract, vitamins and fruit juice concentrate;

[0024] S2: Mix the components in S1 to prepare an adhesive solution;

[0025] The specific steps in S2 are as follows:

[0026] S21: Add the weighed ingredients into a mixer and mix at room temperature at a speed of 100-200 rpm for 10-15 minutes;

[0027] S22: Dissolve hydroxypropyl methylcellulose in 70% ethanol solution to a concentration of 8% ± 0.5% and extend the stirring time to 5 min (to eliminate undissolved micelles);

[0028] S3: sieving the mixed ingredients and mixing with the binder solution to obtain a wet soft lozenge material;

[0029] The specific steps in S3 are as follows:

[0030] S31: taking out the mixed ingredients and sieving them through a sieve with a mesh size of 6-10;

[0031] S32: The sieved ingredients are put back into the mixer, and the binder solution is slowly added to form a soft lozenge material.

[0032] The mixer speed is 80-150 rpm and the mixing time is 10-15 minutes.

[0033] S4: drying the wet soft lozenge material after tableting to obtain dried lozenges.

[0034] The specific steps in S4 are as follows:

[0035] S41: The wet soft lozenge material is removed from the mixer, passed through a 16-20 mesh screen to prepare uniform wet granules, and the wet granules are placed in a fluidized bed dryer for drying; the fluidized bed dryer temperature is 45-60°C, and the drying time is 20-60 minutes; after drying, the moisture content of the granules is controlled at 2.0%-3.0% (monitored by a rapid moisture meter).

[0036] S42: adding magnesium stearate to the dried granules and mixing at a speed of 60-80 rpm for 5-10 minutes;

[0037] S43: Compress the mixed granules into lozenges using a tablet press, controlling the tablet weight difference within ±5% and the hardness between 5-10kgf to obtain dry lozenges; disintegration time: ≤15min (refer to the "Chinese Pharmacopoeia" buccal tablet standard); friability: ≤0.8% (rotary friability tester test).

[0038] The technical effects achieved by the present invention are:

[0039] The present invention's lozenge formula for increasing nicotinamide mononucleotide content effectively protects NMN from external factors and reduces degradation by adopting nano-fullerene inclusion technology. During the storage period, the actual NMN content can be increased by 20%-30% compared to existing technologies, ensuring that users can consume sufficient NMN and fully utilize its efficacy.

[0040] The present invention discloses a lozenge formula capable of increasing the content of nicotinamide mononucleotide. The formula enhances the stability of the lozenge physically and chemically through the synergistic effect of ingredients such as nano-fullerene inclusions, microcrystalline cellulose, mannitol, hydroxypropyl methylcellulose, and magnesium stearate. After the lozenge is stored in harsh environments such as high temperature and high humidity for 6 months, the NMN content can still be maintained at more than 90% of the initial content, while the NMN content of traditional lozenges under the same conditions drops to about 70% of the initial content. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 This is a composition diagram of Example 1 of the present invention;

[0042] Figure 2 It is a preparation flow chart in Example 4 of the present invention. DETAILED DESCRIPTION

[0043] In order to make the purpose and advantages of the present invention more clearly understood, the present invention is described in detail below with reference to the following examples. It should be understood that the following text is only used to describe one or more specific embodiments of the present invention and does not strictly limit the scope of protection of the present invention.

[0044] Example 1:

[0045] like Figure 1 As shown, a lozenge formula for increasing the content of nicotinamide mononucleotide comprises the following ingredients measured by weight:

[0046] Nicotinamide mononucleotide: 20-30 copies;

[0047] Nano-scale fullerene inclusions: 6-12 parts;

[0048] Fructooligosaccharides: 5-20 parts;

[0049] Microcrystalline cellulose: 6-17 parts;

[0050] Lactose: 5-10 parts;

[0051] Mannitol: 3-10 parts;

[0052] Hydroxypropyl methylcellulose: 2-4 parts;

[0053] Magnesium stearate: 0.3-1 part;

[0054] Ziziphus jujuba seed extract: 1-5 parts;

[0055] Ginkgo biloba extract: 1-5 parts;

[0056] Vitamins: 3-7 parts, including at least one of the following combinations: 1-3 parts vitamin B3 (niacinamide) + 1-2 parts vitamin C + 0.5-1 part vitamin E; 2-4 parts vitamin B complex (B1 / B2 / B6) + 0.5-1 part folic acid; (Note: Vitamin B3 can synergize with NMN to promote NAD+ synthesis, and vitamins C / E enhance the antioxidant system); Fruit juice concentrate: 0.5-2 parts, selected from concentrated juice (solids ≥ 70%) of low water activity fruits (such as blueberries, black currants, cranberries), avoid using citrus (strongly acidic) or melons (high water content).

[0057] The nanoscale effect of the nano-fullerene inclusions, the rapid disintegration properties of microcrystalline cellulose, and the blood circulation-enhancing effects of ginkgo biloba extract collectively promote the release and absorption of NMN in the oral mucosa and gastrointestinal tract. The bioavailability of NMN in the lozenges of this invention is 35%-45% higher than that of conventional lozenges, significantly increasing NAD+ levels in human blood in a relatively short period of time and accelerating the physiological effects of NMN.

[0058] Preparation steps of nano-fullerene inclusions:

[0059] Step 1. Disperse fullerene C60 in anhydrous ethanol (5% w / v) and sonicate (300W, 30min).

[0060] Step 2. Add NMN (fullerene:NMN mass ratio = 1:3) and stir (40°C, 500 rpm, 2 h);

[0061] Step 3. Spray drying (inlet temperature 80°C, outlet temperature 45°C) to obtain nano-inclusion powder with a particle size of ≤100 nm.

[0062] In addition, the Chinese date seed extract and ginkgo leaf extract added to the formula work synergistically with NMN, not only significantly delaying aging, enhancing immunity, and improving metabolic function, but also effectively improving sleep quality, enhancing antioxidant capacity, and promoting blood circulation, comprehensively improving human health.

[0063] At the same time, oligofructose, lactose and mannitol give the lozenges appropriate sweetness and good taste, and magnesium stearate ensures the smooth progress of the tableting process, so that the lozenges have good appearance quality and production efficiency, and are suitable for large-scale industrial production.

[0064] Example 2:

[0065] The specific components are measured by weight:

[0066] Nicotinamide mononucleotide: 20 parts; nano-fullerene inclusions: 6 parts; oligofructose: 10 parts; microcrystalline cellulose: 8 parts; lactose: 6 parts; mannitol: 5 parts; hydroxypropyl methylcellulose: 1.5 parts; magnesium stearate: 0.5 parts; spinach seed extract: 1.5 parts; ginkgo leaf extract: 1.5 parts; vitamins: 3.5 parts; fruit juice concentrate: 1 part.

[0067] Example 3:

[0068] The specific components are measured by weight:

[0069] Nicotinamide mononucleotide: 30 parts; nano-fullerene inclusions: 10 parts; oligofructose: 17 parts; microcrystalline cellulose: 15 parts; lactose: 8 parts; mannitol: 8 parts; hydroxypropyl methylcellulose: 3 parts; magnesium stearate: 0.8 parts; spiny jujube seed extract: 2.5 parts; ginkgo leaf extract: 2.5 parts; vitamins: 5 parts; fruit juice concentrate: 1.5 parts.

[0070] For Examples 1-3, the effects of each component are described in detail:

[0071] Nicotinamide mononucleotide: As a core active ingredient, it is a direct precursor of NAD+. It can quickly replenish the body's NAD+ levels that decrease due to factors such as aging and unhealthy lifestyle habits. This activates longevity proteins, regulates gene expression, promotes DNA repair, and enhances mitochondrial function. It plays a key role in delaying aging, enhancing immunity, and improving metabolic function.

[0072] Nano-scale fullerene inclusions: Prepared using advanced nanotechnology, NMN is encapsulated within them. Fullerene has a unique cage structure and excellent physical and chemical properties. On the one hand, it can effectively protect NMN from external environmental factors (such as oxygen, moisture, temperature, etc.), significantly improving the stability of NMN during storage and reducing degradation, thereby ensuring that the actual NMN content in the lozenge remains at a high level for a long time. On the other hand, the nano-scale size characteristics make the inclusions more easily absorbed by the human body, promoting the release and absorption of NMN in the oral mucosa and gastrointestinal tract, and significantly improving its bioavailability.

[0073] Oligofructose: With good water solubility and moisturizing properties, it not only provides the lozenges with an appropriate sweetness and pleasant taste as a sweetener, but also promotes the growth of beneficial intestinal bacteria, improves the intestinal microecological environment, and helps improve the body's ability to absorb nutrients, indirectly enhancing the efficacy of NMN. Its low-calorie properties also make it suitable for all demographics, especially those concerned about calorie intake.

[0074] Microcrystalline cellulose: As a filler and disintegrant, it can increase the volume and hardness of the lozenges, making them well moldable. In the mouth, microcrystalline cellulose can quickly absorb water and swell, prompting the lozenges to disintegrate quickly, allowing the active ingredients in them to be released more quickly, fully contacting the oral mucosa and improving absorption efficiency;

[0075] Lactose: It has good fluidity and compressibility, which can improve the processing performance of lozenges, make the tableting process smoother, and ensure the quality stability of lozenges. At the same time, lactose has moderate sweetness and can work synergistically with oligofructose to further optimize the taste of lozenges.

[0076] Mannitol: It regulates the sweetness of the lozenges and reduces their hygroscopicity. Its refreshing taste provides a unique taste experience for the lozenges, enhancing the consumer's enjoyment of the product. Furthermore, mannitol's low hygroscopicity reduces the risk of lozenge deterioration due to moisture absorption during storage, helping to maintain the physical stability of the lozenges and the chemical stability of NMN.

[0077] Hydroxypropyl methylcellulose: As a binder, it can tightly bind the various ingredients in the formula together to form a solid lozenge structure. HPMC also has a certain film-forming property, forming a protective film on the surface of the lozenge, further enhancing the stability of the lozenge and preventing the loss of active ingredients and interference from external factors. Furthermore, HPMC can slowly dissolve in the gastrointestinal tract, achieving a sustained release of NMN, extending its duration of action in the body and improving its efficacy.

[0078] Magnesium stearate: As a lubricant, it can reduce the friction between the material and the die during tableting, making the tableting operation smoother, reducing the occurrence of problems such as tablet splitting and sticking, and ensuring the appearance quality and production efficiency of the lozenges;

[0079] Ziziphus jujuba seed extract: It has the effects of calming the mind, nourishing the liver, and reducing perspiration. Adding Ziziphus jujuba seed extract to lozenges can alleviate sleep problems caused by stress, anxiety, and other factors, and improve sleep quality. Good sleep has a positive effect on the body's metabolism, immune system function, and the absorption and utilization of NMN. It works synergistically with NMN to comprehensively improve human health.

[0080] Ginkgo biloba extract: Rich in active ingredients such as flavonoids and terpenoid lactones, it has powerful antioxidant, anti-inflammatory, and blood circulation-enhancing effects. On the one hand, ginkgo biloba extract can work together with NMN to exert antioxidant effects, scavenging free radicals in the body, reducing oxidative stress damage to cells, and enhancing cell vitality; on the other hand, its function of improving blood circulation helps to more quickly and effectively transport NMN to various tissues and organs throughout the body, increasing its bioavailability and further enhancing its efficacy.

[0081] Vitamins: Vitamins can be taken from vitamin A, vitamin B, vitamin C and other vitamin ingredients to meet the vitamin needs of the human body; in addition, vitamins can also be used in combination with probiotics to promote intestinal absorption;

[0082] Fruit juice concentrate: Fruit juice concentrate can be added with fruit juices of different flavors according to production needs. On the one hand, it can increase the taste of the lozenges to meet the needs of different groups of people. On the other hand, it can enrich the taste and make it easier for the consumer to melt in the mouth without having any resistance.

[0083] Example 4:

[0084] like Figure 2 As shown, a method for preparing a lozenge capable of increasing the content of nicotinamide mononucleotide comprises the following steps:

[0085] S1: According to the formula ratio, accurately weigh nicotinamide mononucleotide, nano-fullerene inclusions, oligofructose, microcrystalline cellulose, lactose, mannitol, jujube seed extract, ginkgo leaf extract, vitamins and fruit juice concentrate;

[0086] S2: Mix the components in S1 to prepare an adhesive solution;

[0087] The specific steps in S2 are as follows:

[0088] S21: Add the weighed ingredients into a mixer and mix at room temperature at a speed of 100-200 rpm for 10-15 minutes;

[0089] S22: Dissolve hydroxypropyl methylcellulose in 70% ethanol solution to a concentration of 8% ± 0.5%, and extend the stirring time to 5 minutes (to eliminate undissolved clumps). S3: Sieve the mixed ingredients and mix with the binder solution to obtain a soft lozenge material;

[0090] The specific steps in S3 are as follows:

[0091] S31: taking out the mixed ingredients and sieving them through a sieve with a mesh size of 6-10;

[0092] S32: The sieved ingredients are put back into the mixer, and the binder solution is slowly added to form a soft lozenge material.

[0093] The mixer speed is 80-150 rpm and the mixing time is 10-15 minutes.

[0094] S4: drying the wet soft lozenge material after tableting to obtain dried lozenges.

[0095] The specific steps in S4 are as follows:

[0096] S41: The wet soft lozenge material is removed from the mixer, passed through a 16-20 mesh screen to prepare uniform wet granules, and the wet granules are placed in a fluidized bed dryer for drying; the fluidized bed dryer temperature is 45-60°C, and the drying time is 20-60 minutes; after drying, the moisture content of the granules is controlled to be 2.0%-3.0% (monitored by a rapid moisture meter).

[0097] S42: adding magnesium stearate to the dried granules and mixing at a speed of 60-80 rpm for 5-10 minutes;

[0098] S43: Compress the mixed granules into lozenges using a tablet press, controlling the tablet weight difference within ±5% and the hardness between 5-10kgf to obtain dry lozenges; disintegration time: ≤15min (refer to the "Chinese Pharmacopoeia" buccal tablet standard); friability: ≤0.8% (tested by a rotary friability instrument).

[0099] Example 5

[0100] Test Example 1: Stability comparison test

[0101] Methods: The lozenges of Example 2 (nano-encapsulated group) and the control example (conventional lozenges without NMN encapsulation) were placed in a constant temperature and humidity chamber (40°C ± 2°C, RH 75% ± 5%), and samples were collected on 0 / 1 / 3 / 6 months.

[0102] According to the general rule 0512 of Part IV of the Chinese Pharmacopoeia 2020, the NMN content was determined by HPLC:

[0103] Chromatographic column: C18 (4.6×250mm, 5μm); mobile phase: acetonitrile-water (10:90); flow rate: 1.0mL / min; detection wavelength: 260nm;

[0104] result:

[0105]

[0106] Test Example 2: Bioavailability rat experiment

[0107] Methods: SD rats (200 ± 20 g) were randomly divided into 2 groups (n = 6);

[0108] Control group: ordinary NMN lozenges (20 mg / kg);

[0109] Experimental group: Example 3 lozenges (same amount of NMN). Blood was collected at 0.5 / 1 / 2 / 4 / 8 / 12 h after administration, and plasma NMN concentration was detected by LC-MS / MS.

[0110] Results: AUC of the experimental group 0-12hThe relative bioavailability was 142.5±15.7 μg·h / mL (control group: 100.3±11.2 μg·h / mL, P<0.01); the relative bioavailability increased by 42.1%;

[0111] Test Example 3: Verification of the absorption mechanism of nanoinclusions

[0112] Methods: Transmission electron microscopy (TEM): Observe the adhesion state of the nanofullerene inclusions in the lozenges of Example 2 on the intestinal villi of mice; Caco-2 cell model: Compare the NMN transport efficiency (inclusions vs free NMN).

[0113] Results: TEM showed that inclusions (particle size 80-100 nm) were densely attached to the intestinal mucosal folds; the apparent permeability coefficient of NMN in the inclusion group (P app ) was 1.43 times that of the free group.

[0114] The foregoing is merely a preferred embodiment of the present invention. It should be noted that those skilled in the art may make various improvements and modifications without departing from the principles of the present invention, and such improvements and modifications are also within the scope of protection of the present invention. Structures, devices, and operating methods not specifically described or explained herein shall, unless otherwise specified or limited, be implemented in accordance with conventional means in the art.

Claims

1. A lozenge formula capable of increasing the content of nicotinamide mononucleotide, characterized by: The composition is measured by weight and includes the following ingredients: Nicotinamide mononucleotide: 20-30 copies; Nano-scale fullerene inclusions: 6-12 parts; Fructooligosaccharides: 5-20 parts; Microcrystalline cellulose: 6-17 parts; Lactose: 5-10 parts; Mannitol: 3-10 parts; Hydroxypropyl methylcellulose: 2-4 parts; Magnesium stearate: 0.3-1 part; Ziziphus jujuba seed extract: 1-5 parts; Ginkgo biloba extract: 1-5 parts; Vitamins: 3-7 parts, including at least one of the following combinations: 1-3 parts vitamin B3, 1-2 parts vitamin C, 0.5-1 part vitamin E; 2-4 parts vitamin B complex, 0.5-1 part folic acid; Juice concentrate: 0.5-2 parts, selected from the concentrate of low water activity fruits, no citrus or melon.

2. The lozenge formula for increasing the content of nicotinamide mononucleotide according to claim 1, characterized in that: The specific components are measured by weight: Nicotinamide mononucleotide: 20 parts; Nano-fullerene inclusions: 6 parts; Fructooligosaccharides: 10 parts; Microcrystalline cellulose: 8 parts; Lactose: 6 parts; Mannitol: 5 parts; Hydroxypropyl methylcellulose: 1.5 parts; Magnesium stearate: 0.5 parts; Ziziphus jujuba seed extract: 1.5 parts; Ginkgo biloba leaf extract: 1.5 parts; Vitamins: 3.5 parts; Fruit juice concentrate: 1 part.

3. The lozenge formula for increasing the content of nicotinamide mononucleotide according to claim 1, characterized in that: The specific components are measured by weight: Nicotinamide mononucleotide: 30 parts; Nano-fullerene inclusions: 10 parts; Fructooligosaccharides: 17 parts; Microcrystalline cellulose: 15 parts; Lactose: 8 parts; Mannitol: 8 parts; Hydroxypropyl methylcellulose: 3 parts; Magnesium stearate: 0.8 parts; Ziziphus jujuba seed extract: 2.5 parts; Ginkgo biloba leaf extract: 2.5 parts; Vitamins: 5 parts; Fruit juice concentrate: 1.5 parts.

4. A method for preparing a lozenge capable of increasing the content of nicotinamide mononucleotide, characterized by: The following steps are involved: S1: According to the formula ratio, accurately weigh nicotinamide mononucleotide, nano-fullerene inclusions, oligofructose, microcrystalline cellulose, lactose, mannitol, jujube seed extract, ginkgo leaf extract, vitamins and fruit juice concentrate; S2: Mix the components in S1 to prepare an adhesive solution; S3: sieving the mixed ingredients and mixing with the binder solution to obtain a wet soft lozenge material; S4: drying the wet soft lozenge material after tableting to obtain dried lozenges.

5. The method for preparing a lozenge capable of increasing the content of nicotinamide mononucleotide according to claim 4, characterized in that: The specific steps in S2 are as follows: S21: Add the weighed ingredients into a mixer and mix at room temperature at a speed of 100-200 rpm for 10-15 minutes; S22: Dissolve hydroxypropyl methylcellulose in 70% ethanol solution to a concentration of 8% ± 0.5% and extend the stirring time to 5 minutes.

6. The method for preparing a lozenge capable of increasing the content of nicotinamide mononucleotide according to claim 4, characterized in that: The specific steps in S3 are as follows: S31: taking out the mixed ingredients and sieving them through a sieve with a mesh size of 6-10; S32: The sieved ingredients are put back into the mixer, and the binder solution is slowly added to form a soft lozenge material.

7. The method for preparing a lozenge capable of increasing the content of nicotinamide mononucleotide according to claim 4, characterized in that: The specific steps in S4 are as follows: S41: The wet soft lozenge material is taken out from the mixer, passed through a 16-20 mesh screen to prepare uniform wet granules, and the wet granules are placed in a fluidized bed dryer for drying. After drying, the moisture content of the granules is controlled at 2.0%-3.0%, and the moisture content is monitored using a rapid moisture meter; S42: adding magnesium stearate to the dried granules and mixing at a speed of 60-80 rpm for 5-10 minutes; S43: The mixed granules are compressed into lozenges using a tablet press, with the weight variation of the tablets controlled within ±5% and the hardness between 5-10 kgf, to obtain dried lozenges.

8. The method for preparing a lozenge capable of increasing the content of nicotinamide mononucleotide according to claim 4, characterized in that: In the step S32, the mixer rotates at a speed of 80-150 rpm, and the mixing time is 10-15 minutes.

9. The method for preparing a lozenge capable of increasing the content of nicotinamide mononucleotide according to claim 4, characterized in that: In the step S41, the temperature of the fluidized bed dryer is 45-60° C., and the drying time is 20-60 minutes.

Images